Exclusive Summary

• - No patent barriers and listed on the WHO Essential Medicines List, enabling fast registration and multi-market distribution.
• - Dual concentrations (5 g/10 mL, 50% and 2.5 g/10 mL, 25%) fit obstetric and emergency use, reducing preparation errors and aligning with varied guidelines.
• - Addresses ~2.8–11.2 million preeclampsia/eclampsia cases annually and severe asthma exacerbations within 262 million global patients, ensuring strong hospital demand.
• - China market No.1 capacity and reliable supply help mitigate injectable shortages, suitable for tenders and emergency stockpiles.
• - Very low-cost injectable; LMIC tender prices often around $0.05–0.30 per 10 mL ampoule, offering clear price competitiveness.